Business
Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
Novel E3 ligase identified by Kymera’s Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells Novel STAT3 degrader enabled
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"Novel E3 ligase identified by Kymera’s Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells Novel STAT3 degrader enabled by PegasusTM platform, and based on identified novel ligase, demonstrates proof-of-concept degradation across multiple in vitro cancer cell lines New preclinical findings presented today at inaugural Ligase Targeting Drug Development Summit WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today presented new data demonstrating proof-of-concept for its PegasusTM platform, including the identification and characterization of a novel and previously unliganded E3 ligase with restricted expression in healthy tissues while broadly expressed in cancer cells, as determined by proteomics. Kymera discovered novel ligands for this ligase using state-of-the-art hit finding techniques and subsequently designed a novel proof-of-concept STAT3 degrader compound based on this novel E3 ligase. The degrader demonstrated potent and dose-dependent degradation of STAT3 across multiple cancer cell lines. These data are being presented by Chris De Savi, PhD, Vice President, Head of Drug Discovery at Kymera, today at the inaugural Ligase Targeting Drug Development Summit, taking place virtually from May 25-27, 2021. “Kymera was founded and empowered to push the boundaries of targeted protein degradation to discover and develop novel, life-changing therapies. A key initiative in our discovery efforts is to discover a new generation of tissue-selective or -restrictive degrader medicines with the goal of drugging an entirely new set of protein targets. We believe the future of targeted protein degradation will rely on exploiting novel E3 ligases with diverse tissue expression profiles, enabling medicines with selective degradation in disease-relevant tissues, and potentially unlocking a therapeutic paradigm shift,\" said Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics. “We look forward to building on these findings as we expand our pipeline of innovative therapeutic candidates and advance our novel E3 ligase-enabled pipeline.” Kymera has identified the expression profiles of approximately 600 ...